A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk

A Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Administration, Dose-escalation Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics Characteristics and the Effect of Food on Pharmacokinetics of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk

This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

103

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

- All participants must:1, Healthy adult participants, regardless of gender, aged between 18 and 65 years old when the informed consent is signed; 2,Male participants with a body weight of >= 50.0 kg, female participants with a body weight of >= 45.0 kg; 3, Those who can understand the informed consent form, voluntarily participate in the trial and sign the informed consent form.

Exclusion Criteria:

  1. Individuals with allergic constitution, or those with a history of clinically significant food, drug allergies or other allergic reactions as determined by the investigators; or those who are known to be allergic to NLRP3 inhibitors or to the excipient ingredients of the IP;
  2. Diabetes mellitus;
  3. Hypertension;
  4. Hepatobiliary diseases;
  5. Alcoholism;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single-ascending Dose (SAD) study and Food Effect (FE) study

The SAD portion of the study consists of 5 cohorts. Dosing in these cohorts will precede sequentially: 5 mg, 10 mg, 25 mg, 40 mg and 50 mg cohorts.

Experimental: Multiple-ascending Doses (MAD) study

The MAD portion of the study consists of 3 cohorts. Dosing in these cohorts will precede sequentially:10 mg, 25 mg and 40 mg cohorts.

Experimental: Obesity with cardiovascular risk study

This study intends to set up 2 dose cohorts, temporarily as follows: 1) 10 mg QD cohort, 2) 25 mg QD cohort.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of adverse events
Time Frame: Day 1 to Day 21

including hematology, blood biochemistry, urinalysis, and coagulation function

Day 1 to Day 21

Secondary Outcome Measures

Outcome Measure
Time Frame
ZL65 Pharmacokinetics (PK):Cmax
Time Frame: 0-144 hours
0-144 hours
ZL65 Pharmacokinetics (PK):Tmax
Time Frame: 0-144 hours
0-144 hours
ZL65 Pharmacokinetics (PK):AUC0-t
Time Frame: 0-144 hours
0-144 hours
ZL65 Pharmacokinetics (PK):t1/2
Time Frame: 0-144 hours
0-144 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ofer Gonen, Doctor, Nucleus Network Pty Ltd Commercial Road

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 19, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

December 30, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 18, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • O-ZL65-PI-I

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.